Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”This is worrying.
The Tribune newspaper in India is reporting that authorities have asked for the immediate suspension of use (and quarantining) of six batches of plasma derived factor IX concentrate for use in haemophilia B.
The products are made by a company called ICHOR Biologics, a company I have not heard of before.
The article is missing two critical pieces of information:
a) What is the adverse event that led to the suspension of this product
b) How many patients are affected. Only the total number of patients in the region are given.
I really hope this is not new transmission of a viral infection in persons with haemophilia.
The story may be a local one in Punjab in India, but the international world of haemophilia will be following this story.”
Read The Tribune article here.
Stay updated on the emerging with Hemostasis Today.
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025
-
Mar 12, 2026, 16:36Giordano Botta: From the ‘Power of Zero’ to a Precise Understanding of Cardiovascular Risk
-
Mar 12, 2026, 16:31Katie Baca-Motes: Incorporating Menstrual Cycle and Hormonal Rhythms Into Clinical Research
-
Mar 12, 2026, 16:22Augustina Isioma Ikusemoro: Quality Indicators in Processed Blood Components
-
Mar 12, 2026, 16:20Aryabhatta Sadhu: The Full Spectrum of Transplant Immunology and Clinical Care
-
Mar 12, 2026, 16:17Megan Adediran: Building Pathways to Sustainable Care for People With Bleeding Disorders in Nigeria
-
Mar 12, 2026, 16:09Rob Mac Sweeney: Hemodynamic Failure During Sepsis
-
Mar 12, 2026, 16:06Haroun Gajraj: Shortwave Diathermy for Facial Spider Veins